☰

Neelanjana Ray, Ph.D. - Publications

Affiliations: 
2004 Princeton University, Princeton, NJ 
Area:
virology, circuit tracers, pathogenesis
Tree Info Grants Similar researchers PubMed Report error

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Dicker I, Zhang S, Ray N, Beno BR, Regueiro-Ren A, Joshi S, Cockett M, Krystal M, Lataillade M. Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study. Plos One. 14: e0224076. PMID 31622432 DOI: 10.1371/Journal.Pone.0224076  0.415
2017 Gay CL, Bosch RJ, Ritz J, Hataye JM, Aga E, Tressler RL, Mason SW, Hwang CK, Grasela DM, Ray N, Cyktor JC, Coffin JM, Acosta EP, Koup RA, Mellors JW, et al. Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy. The Journal of Infectious Diseases. PMID 28431010 DOI: 10.1093/Infdis/Jix191  0.341
2017 Hwang C, Schürmann D, Sobotha C, Boffito M, Sevinsky H, Ray N, Ravindran P, Xiao H, Keicher C, Hüser A, Krystal M, Dicker IB, Grasela D, Lataillade M. Antiviral Activity, Safety, and Exposure-Response relationships of GSK3532795, a Second-Generation HIV-1 Maturation Inhibitor, administered as Monotherapy or in Combination with Atazanavir±Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002). Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 28369211 DOI: 10.1093/Cid/Cix239  0.409
2017 Ray N, Li T, Lin Z, Protack T, Maria van Ham P, Hwang C, Krystal M, Nijhuis M, Lataillade M, Dicker I. The second-generation maturation inhibitor GSK3532795 maintains potent activity toward HIV protease inhibitor-resistant clinical isolates. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 28234686 DOI: 10.1097/Qai.0000000000001304  0.373
2016 Gupta SK, McComsey GA, Lombaard J, Echevarría J, Orrell C, Avihingsanon A, Osiyemi O, Santoscoy M, Ray N, Stock DA, Joshi SR, Hanna GJ, Lataillade M. Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial. The Lancet. Hiv. 3: e13-22. PMID 26762988 DOI: 10.1016/S2352-3018(15)00231-3  0.326
2014 Zhou N, Nowicka-Sans B, McAuliffe B, Ray N, Eggers B, Fang H, Fan L, Healy M, Langley DR, Hwang C, Lataillade M, Hanna GJ, Krystal M. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068. The Journal of Antimicrobial Chemotherapy. 69: 573-81. PMID 24128669 DOI: 10.1093/Jac/Dkt412  0.42
2013 Li Z, Zhou N, Sun Y, Ray N, Lataillade M, Hanna GJ, Krystal M. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors. Antimicrobial Agents and Chemotherapy. 57: 4172-80. PMID 23774428 DOI: 10.1128/Aac.00513-13  0.374
2013 Ray N, Hwang C, Healy MD, Whitcomb J, Lataillade M, Wind-Rotolo M, Krystal M, Hanna GJ. Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068. Journal of Acquired Immune Deficiency Syndromes (1999). 64: 7-15. PMID 23614999 DOI: 10.1097/Qai.0B013E31829726F3  0.415
2012 Nettles RE, Schürmann D, Zhu L, Stonier M, Huang SP, Chang I, Chien C, Krystal M, Wind-Rotolo M, Ray N, Hanna GJ, Bertz R, Grasela D. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. The Journal of Infectious Diseases. 206: 1002-11. PMID 22896665 DOI: 10.1093/Infdis/Jis432  0.441
2012 Nowicka-Sans B, Gong YF, McAuliffe B, Dicker I, Ho HT, Zhou N, Eggers B, Lin PF, Ray N, Wind-Rotolo M, Zhu L, Majumdar A, Stock D, Lataillade M, Hanna GJ, et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrobial Agents and Chemotherapy. 56: 3498-507. PMID 22547625 DOI: 10.1128/Aac.00426-12  0.422
2010 Tilton JC, Amrine-Madsen H, Miamidian JL, Kitrinos KM, Pfaff J, Demarest JF, Ray N, Jeffrey JL, Labranche CC, Doms RW. HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry. Aids Research and Human Retroviruses. 26: 13-24. PMID 20055594 DOI: 10.1089/Aid.2009.0132  0.387
2010 Ray N, Whidby J, Stewart S, Hooper JW, Bertolotti-Ciarlet A. Study of Andes virus entry and neutralization using a pseudovirion system Journal of Virological Methods. 163: 416-423. PMID 19903496 DOI: 10.1016/J.Jviromet.2009.11.004  0.353
2009 Ray N. Maraviroc in the treatment of HIV infection. Drug Design, Development and Therapy. 2: 151-61. PMID 19920903 DOI: 10.2147/Dddt.S3474  0.406
2009 Pugach P, Ray N, Klasse PJ, Ketas TJ, Michael E, Doms RW, Lee B, Moore JP. Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology. 387: 296-302. PMID 19303620 DOI: 10.1016/J.Virol.2009.02.044  0.382
2009 Ray N, Blackburn LA, Doms RW. HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide. Journal of Virology. 83: 2989-95. PMID 19153234 DOI: 10.1128/Jvi.02496-08  0.318
2008 Harrison JE, Lynch JB, Sierra LJ, Blackburn LA, Ray N, Collman RG, Doms RW. Baseline resistance of primary human immunodeficiency virus type 1 strains to the CXCR4 inhibitor AMD3100. Journal of Virology. 82: 11695-704. PMID 18799588 DOI: 10.1128/Jvi.01303-08  0.449
2008 Dey AK, David KB, Ray N, Ketas TJ, Klasse PJ, Doms RW, Moore JP. N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus. Virology. 372: 187-200. PMID 18031785 DOI: 10.1016/J.Virol.2007.10.018  0.352
2007 Ray N, Harrison JE, Blackburn LA, Martin JN, Deeks SG, Doms RW. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. Journal of Virology. 81: 3240-50. PMID 17251281 DOI: 10.1128/Jvi.02413-06  0.414
2004 Ray N, Bisher ME, Enquist LW. Cyclooxygenase-1 and -2 are required for production of infectious pseudorabies virus. Journal of Virology. 78: 12964-74. PMID 15542648 DOI: 10.1128/Jvi.78.23.12964-12974.2004  0.513
2004 Ray N, Enquist LW. Transcriptional response of a common permissive cell type to infection by two diverse alphaherpesviruses. Journal of Virology. 78: 3489-501. PMID 15016872 DOI: 10.1128/Jvi.78.7.3489-3501.2004  0.486
Show low-probability matches.